COVID-19 pneumonia
Conditions
Interventions
Control group:Mild and ordinary people: type I interferon autoantibody detection
Experimental group:Severe and critical: type I interferon autoantibody detection
Sponsors
Shanghai Sixth Hospital, Shanghai Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Confirmed cases meeting the diagnostic criteria for novel coronavirus; 2. Suspected cases. Any 1 of the following epidemiological history, and any 2 of the clinical manifestations; no clear epidemiological history, 3 of the clinical manifestations; or any 2 of the clinical manifestations At the same time, the new coronavirus-specific IgM antibody is positive (those who have recently been vaccinated against the new coronavirus vaccine are not used as reference indicators): (1) Epidemiological history: 1) There is a travel history or residence history in the case report community within 14 days before the onset of illness; 2) Have a history of contact with a person infected with the new coronavirus within 14 days before the onset; 3) Have been in contact with patients with fever or respiratory symptoms from communities with case reports within 14 days before onset; 4) Clustered onset (2 or more cases of fever and/or respiratory symptoms in a small area such as home, office, school class, etc. within 14 days); (2) Clinical manifestations: 1) Clinical manifestations related to novel coronavirus pneumonia such as fever and (or) respiratory symptoms; 2) Possess the imaging features of the above-mentioned novel coronavirus pneumonia; 3) The total number of white blood cells is normal or decreased in the early stage of onset, and the lymphocyte count is normal or decreased; 3. Over 18 years old; 4. Has signed the informed consent form, and is able and willing to complete the entire prescribed research plan and follow-up during the entire follow-up study period.
Exclusion criteria
Exclusion criteria: 1. Known pregnant or lactating women; 2. The investigator judges that continuing the research may be unfavorable to the subject, such as severe anemia or severe coagulation disorders, etc., it is not suitable to draw peripheral blood for testing; 3. The patient participated in other clinical trials at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| autoantibodies against type I IFNs; | — |
Countries
China
Contacts
Public ContactJie Chen
Shanghai Sixth Hospital, Shanghai Jiaotong University
Outcome results
None listed